Michael Dunn, MD*

Michael Dunn, MD*

Appointments/Affiliations: 

Professor
Departments of Medicine and Biomedical Informatics

Presbyterian University Hospital, M2, C Wing
200 Lothrop Street
Pittsburgh, PA 15213

Liver-Related Work

Clinical and Research Interests: I am a hepatologist and Associate Chief for Translational Research of the Division of Gastroenterology, Hepatology and Nutrition. My major current interest is understanding, preventing, and reversing physical decline and muscle wasting in cirrhosis, the major cause of death and waitlist attrition in liver transplantation. I am experienced in analysis of data from electronic records for improved predictive modeling and decision support.  I am interested in team dynamics and leader development at all levels, having successfully led US and multinational military clinical and research organizations during 28 years of Army service, completed as a Brigadier General.
 
Ongoing Research Studies:
  1. I formed and now lead the FLEXIT (Fitness, Life Enhancement and Exercise in Transplantation) Consortium of investigators at the University of California San Francisco, Mayo Clinic Arizona, Cleveland Clinic, Duke University, University of Alberta, and University of Pittsburgh, engaged in multi-center collaborations to define, prevent and reverse physical decline in cirrhosis. 
  2. In collaboration with colleagues of the Thomas E Starzl Transplantation Institute and the School of Health and Rehabilitation Sciences, I lead a UPMC hospital-funded initiative to improve the fitness and activity of liver transplant candidates with the objective of producing a 20 percent decrease in waitlist hospital days and waitlist mortality. We are exploring wearable personal activity monitoring and quantitation of muscle mass with imaging segmentation analysis as enabling technologies.
  3. I helped Dr. David Binion design and continue to assist in operating a Department of Defense supported searchable prospective electronic clinical registry for our inflammatory bowel disease team.  It has enabled significant advances in disease modeling with over 20 major publications in the last 3 years.
  4. I am site Principal Investigator of a new industry-sponsored FDA registration trial of obeticholic acid therapy for primary sclerosing cholangitis.
  5. I collaborate with Dr. Mark Roberts of the Graduate School of Public Health on a Commonwealth of Pennsylvania funded analysis of policy options in treatment of hepatitis C in Medicaid recipients. I apply my Federal organization and execution experience in working with the Pittsburgh Veterans Affairs Health Care System in a major effort to eliminate hepatitis C infection in the region’s Veterans.

Research Service: My team provides software and analytic support for multiple colleagues interested in quantitating muscle mass on cross sectional imaging. We also have developed an IRB-approved pathway available for faculty colleagues who may want to explore clinical applications of wearable physical activity monitoring.


 

 

Special Interest Groups: 
Chronic Liver Injury